Amgen has officially launched its new commercial office in Hong Kong, marked by an internal celebration that took place at the Company’s regional headquarters in Hong Kong on August 10.
Amgen’s entry into Hong Kong and Macau will enhance the exchange of scientific ideas, foster more research collaborations and bring innovative therapies for grievous illnesses to local patients. For Amgen, it is an important step in the Company’s global expansion efforts. The Company’s Japan Asia Pacific (JAPAC) regional headquarters are also based at its One Island East offices, Taikoo Place, Hong Kong.
“In 2007, Amgen opened a small clinical development hub in Hong Kong with fewer than ten people. Today, we are delighted to launch our Hong Kong/Macau commercial office. We expect to employ more than 80 people by the end of the year in Hong Kong, serving patients locally and in the rest of the JAPAC region,” said Penny Wan, regional vice president and general manager of Amgen’s JAPAC region.
Amgen’s initial priorities in Hong Kong and Macau will include:
- Working with healthcare providers and payers to ensure the patients who can benefit from Amgen’s approved medicines can access them;
- Advancing its clinical pipeline, which includes treatments for bone disease, cardiovascular, hematology / oncology, nephrology, inflammation, neuroscience and biosimilar medicines;
- Being an active member in the local biotechnology industry to encourage mutual growth while contributing to the ongoing creation of an environment where the industry can thrive in Hong Kong and Macau.
To learn more, visit amgen.hk